Jyoti Malhotra, MD, MPH, joins The Moonlight Shift to discuss first-in-human phase 1 lung cancer trials, healthcare access, and her work at Yale Cancer Center.
|Articles|May 14, 2015
Rebecca Lehto on Complementary Modalities During Lung Cancer Treatment
Author(s)Rebecca Lehto, PhD, RN, OCN
Rebecca Lehto, PhD, RN, OCN, discusses patient use of complementary modalities during treatment for advanced lung cancer.
Advertisement
Rebecca Lehto, PhD, RN, OCN, assistant professor, College of Nursing, Michigan State University, discusses patient use of complementary modalities during treatment for advanced lung cancer.
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
2
Beyond the Treatment Center: Exploring Equine Assisted Wellness
3
Future Directions in Metastatic Triple-Negative Breast Cancer Care
4
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
5